This company has been marked as potentially delisted and may not be actively trading. Seneca Biopharma (SNCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SNCA vs. IKT, IZTC, JATT, CRTX, ZIVO, ALVR, FNCH, SRNE, SQZ, and NKGNShould you be buying Seneca Biopharma stock or one of its competitors? The main competitors of Seneca Biopharma include Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), JATT Acquisition (JATT), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), AlloVir (ALVR), Finch Therapeutics Group (FNCH), Sorrento Therapeutics (SRNE), SQZ Biotechnologies (SQZ), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector. Seneca Biopharma vs. Its Competitors Inhibikase Therapeutics Invizyne Technologies JATT Acquisition Cortexyme ZIVO Bioscience AlloVir Finch Therapeutics Group Sorrento Therapeutics SQZ Biotechnologies NKGen Biotech Inhibikase Therapeutics (NYSE:IKT) and Seneca Biopharma (NASDAQ:SNCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Do institutionals & insiders hold more shares of IKT or SNCA? 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 5.2% of Seneca Biopharma shares are owned by institutional investors. 7.3% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 2.1% of Seneca Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend IKT or SNCA? Inhibikase Therapeutics currently has a consensus price target of $8.00, suggesting a potential upside of 400.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Inhibikase Therapeutics is more favorable than Seneca Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Seneca Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is IKT or SNCA more profitable? Inhibikase Therapeutics has a net margin of 0.00% compared to Seneca Biopharma's net margin of -230.34%. Seneca Biopharma's return on equity of -122.20% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% Seneca Biopharma -230.34%-122.20%-110.61% Which has more risk and volatility, IKT or SNCA? Inhibikase Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Seneca Biopharma has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Does the media favor IKT or SNCA? In the previous week, Inhibikase Therapeutics' average media sentiment score of 0.00 equaled Seneca Biopharma'saverage media sentiment score. Company Overall Sentiment Inhibikase Therapeutics Neutral Seneca Biopharma Neutral Which has preferable valuation and earnings, IKT or SNCA? Seneca Biopharma has higher revenue and earnings than Inhibikase Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.60Seneca Biopharma$10K3,199.76-$8.35MN/AN/A SummarySeneca Biopharma beats Inhibikase Therapeutics on 6 of the 11 factors compared between the two stocks. Get Seneca Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SNCA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNCA vs. The Competition Export to ExcelMetricSeneca BiopharmaBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.00M$357.29M$6.11B$10.47BDividend YieldN/AN/A5.73%4.77%P/E RatioN/AN/A85.3627.36Price / Sales3,199.76500.80607.44135.43Price / CashN/A22.4437.4661.86Price / Book1.393.8812.426.81Net Income-$8.35M-$133.30M$3.32B$276.80M Seneca Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNCASeneca BiopharmaN/A$1.85flatN/A-45.7%$32.00M$10K0.007IKTInhibikase Therapeutics1.2825 of 5 stars$1.66flat$6.50+291.6%+1.9%$123.70MN/A-0.626Gap DownIZTCInvizyne TechnologiesN/A$13.07-3.2%N/AN/A$81.71MN/A0.0029JATTJATT AcquisitionN/A$4.34+8.8%N/A-52.7%$74.87MN/A0.003Gap DownHigh Trading VolumeCRTXCortexymeN/A$1.92+7.9%N/A+169.5%$57.89MN/A-0.6555ZIVOZIVO Bioscience0.1095 of 5 stars$13.01+8.4%N/A-34.6%$49.66M$15.85K-2.6710Gap UpALVRAlloVirN/A$6.59-14.6%N/A-75.8%$33.23MN/A-0.33110High Trading VolumeFNCHFinch Therapeutics GroupN/A$12.15+0.4%N/A+3.9%$19.51MN/A-1.38190SRNESorrento Therapeutics0.8855 of 5 stars$0.01+11.1%N/A+66.7%$2.76M$60.32M0.00800Gap UpHigh Trading VolumeSQZSQZ BiotechnologiesN/A$0.02-17.9%N/A+21.7%$678K$18.16M-0.011,620NKGNNKGen Biotech0.135 of 5 stars$0.00+66.7%N/A-91.9%$45KN/A0.00N/AGap Up Related Companies and Tools Related Companies Inhibikase Therapeutics Alternatives Invizyne Technologies Alternatives JATT Acquisition Alternatives Cortexyme Alternatives ZIVO Bioscience Alternatives AlloVir Alternatives Finch Therapeutics Group Alternatives Sorrento Therapeutics Alternatives SQZ Biotechnologies Alternatives NKGen Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNCA) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seneca Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seneca Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
